Biotech’s Initial Step: Blockchain Treasury Focuses on Crypto’s Most Rapidly Expanding Industry
- Enlivex Therapeutics raises $212M via private placement to adopt RAIN, a blockchain-based prediction market token, marking the first U.S. public company to use such a treasury strategy. - Funds will prioritize RAIN token accumulation as primary reserve, with proceeds also supporting clinical trials for its osteoarthritis therapy and a new board member, former Italian PM Matteo Renzi. - The move aligns with rising institutional interest in prediction markets but introduces risks from token volatility, reg
Enlivex Therapeutics (ENLV), a biotechnology company listed on Nasdaq, has secured $212 million via a private placement to implement an innovative treasury approach focused on RAIN, a blockchain-based token for prediction markets,
The capital raise involved issuing 212 million shares at $1.00 each,
Enlivex’s initiative reflects a rising trend of institutional involvement in prediction markets,
The deal, anticipated to finalize by November 25, 2025, is being managed by BTIG as the exclusive placement agent
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OKTA, INC. <OKTA.O>: JEFFERIES RAISES TARGET PRICE TO $240 FROM $200
CSX CORPORATION <CSX.O>: RBC CUTS TARGET PRICE TO $53 FROM $54
CANADIAN PACIFIC KANSAS CITY <CP.TO>: RBC RAISES TARGET PRICE TO C$146 FROM C$145
M&T BANK CORPORATION <MTB.N>: JEFFERIES CUTS TARGET PRICE TO $275 FROM $300